Last reviewed · How we verify
Colchicine 0.6 mg
At a glance
| Generic name | Colchicine 0.6 mg |
|---|---|
| Also known as | GOUTNOR 0.6 mg Tablet, Prophylaxis, Colcrys, Gloperba, Lodoco |
| Sponsor | CHA University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Mechanistic Clinical Trial of Colchicine in Patients With Peripheral Artery Disease (EARLY_PHASE1)
- The Peri-OPerative COlchicine to Reduce Negative Events (POPCORN) Trial (PHASE4)
- MACT (Mono Antiplatelet and Colchicine Therapy) Prospective Multicenter Study (PHASE4)
- Colchicine's Effect on Inflammatory Markers (PHASE4)
- A Randomized Multicenter Study for Isolated Skin Vasculitis (PHASE2)
- Treat-to-Target Serum Urate Versus Treat-to-Avoid Symptoms in Gout (PHASE4)
- Colchicine to Suppress Inflammation and Improve Insulin Resistance in Adults and Adolescents With Obesity (PHASE2)
- Perioperative Colchicine for TKA (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Colchicine 0.6 mg CI brief — competitive landscape report
- Colchicine 0.6 mg updates RSS · CI watch RSS
- CHA University portfolio CI